Adam L. Boxer MD PhD

Neurology•San Francisco, CA

Endowed Professor in Memory and Aging, University of California, San Francisco

Join to View Full Profile

675 Nelson Rising LaneSuite 190San Francisco, CA 94143
Phone+1 415-353-2057
Fax+1 415-353-8292

Education & Training

Stanford Health Care-Sponsored Stanford UniversityResidency, Neurology, 1999 - 2002
Sutter Health/California Pacific Medical CenterInternship, Internal Medicine, 1998 - 1999
New York University School of MedicineClass of 1998

Certifications & Licensure

CA State Medical License 1999 - 2027
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Start of enrollment: 2007 Oct 01
Completed
Phase 4
Davunetide (AL-108) in Predicted Tauopathies - Pilot Study Start of enrollment: 2010 Jan 01
Completed
Phase 1
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort Start of enrollment: 2012 Jul 01
Recruiting
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
RECRUITING
PHASE2, PHASE3
4 Repeat Tauopathy Neuroimaging Initiative Start of enrollment: 2011 Jan 10
COMPLETED
Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations Start of enrollment: 2013 Mar 01
Completed
Phase 1
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Start of enrollment: 2013 Jul 01
Terminated
Phase 3
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease Start of enrollment: 2013 Nov 01
Completed
Phase 1
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Start of enrollment: 2014 Feb 28
Completed
Phase 3
Safety Study of TPI-287 to Treat CBS and PSP Start of enrollment: 2014 May 01
Completed
Phase 1
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy Start of enrollment: 2015 Apr 01
Completed
Phase 1
Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Start of enrollment: 2015 Jul 01
Completed
Phase 1
Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 Start of enrollment: 2016 Feb 22
Terminated
Phase 1
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
COMPLETED
Intranasal Oxytocin for Frontotemporal Dementia Start of enrollment: 2018 Jan 31
Active, not recruiting
Phase 2
Salsalate in Patients Mild to Moderate Alzheimer's Disease Start of enrollment: 2017 Jul 21
COMPLETED
PHASE1
BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES Start of enrollment: 2018 Sep 12
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Functional Connectivity Associations With Markers of Disease Progression in GRN Pathogenic Variant Carriers.
Taru M Flagan, Stephanie A Chu, Suvi Häkkinen, Liwen Zhang, David McFall
Annals of Clinical and Translational Neurology. 2025-09-16
Neurodegenerative plasma biomarkers for prediction of hippocampal atrophy in older adults with suspected Alzheimer's disease in Kinshasa, Democratic Republic of Congo.
Jean Ikanga, Kharine Jean, Priscilla Medina, Saranya Sundaram Patel, Megan Schwinne
Journal of Alzheimer's Disease. 2025-09-01
Plasma lipidome dysregulation in frontotemporal dementia reveals shared, genotype-specific, and severity-linked alterations.
Yohannes A Ambaw, Peter A Ljubenkov, Shubham Singh, Abdi Hamed, Sebastian Boland
Alzheimer's & Dementia. 2025-09-01

Press Mentions

How Do Middle-Aged Folks Get Dementia? It Could Be These ProteinsMay 14th, 2025
International Neurology Conference Featured UCSF ExpertsApril 22nd, 2025
New Hope for Progressive Supranuclear Palsy with Innovative TrialSeptember 3rd, 2024
Join now to see all

Grant Support

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2)MAYO CLINIC ROCHESTER2019–2030
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
The Alzheimer's Disease Tau Platform Clinical TrialUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2023–2028
Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDPUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2021–2026
Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDPUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2021–2026
Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDPUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2021–2026
Biomarker Evaluation in Young Onset Dementia from Diverse Populations (BEYONDD)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2022–2025
Eye Movement Control In Normal Elderly And MCINational Institute On Aging2009–2012
Four Repeat Tauopathy Neuroimaging InitiativeNational Institute On Aging2010–2011
Ocular Motor Function And Decision-Making In FTLDNational Institute Of Neurological Disorders And Stroke2005–2009

Adam L. Boxer MD PhD

Dr. Boxer is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.